Translation Transcription Infidelity (TI)
Into Multiple Affordable Cures
For Both Human and Animals


Genclis SA is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (“TI”). TI is a patented process that begins by analyzing differences between RNA and DNA sequences to identify translated proteins capable of causing the production of either Immunoglobulin E (“IgE”), the antibody responsible for most forms of allergies or Immunoglobulin G (“IgG”), the workhorse of immunity that accounts for most of vaccine efficacy. Genclis uses its proprietary patented platform technology to develop therapies that elicit self-produced antibodies that block disease-causing proteins irrespective of their endogenous or exogenous origin.



dna 1903318

Science of TI

Transcription infidelity An Ubiquitous Biological process

Read more about Science of TI



GENCLIS is a Research and Development company, focused on harnessing humoral immunity to produce novel diagnostic and therapeutic solutions addressing unmet human and animal needs.

Genclis’s technology relies on its proprietary discovery of Transcription Infidelity (TI) * (issued patents) that define both innate and adaptive humoral immunity.

  1. Genclis commercializes pre-clinical and cellular models in allergy and autoimmunity to evaluate novel therapeutic, probiotic and nutritional solutions.
  2. Genclis assists commercial partners in :
    1. Evaluating intrinsic allergenicity of pharmaceutical, food and cosmetic ingredients ;
    2. Etablishing industrial procedures to control or suppress ingredient’s allergenicity ;
  3. Genclis engages in exclusive industrial partnerships for co-development of Transcription Infidelity Assisted Sequential Immunization programs for infectious and immune diseases.
  4. Genclis manufactures and commercializes cutting edge reagents for diagnostic and preclinical use.


For more information, please contact us

To develop tools required for precise medicine


« The difference between a low-intensity signal that precedes any major transformation and noise is that the second is random, while the first is not. »

Bernard Bihain, CEO